Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Accounts Payables (2021 - 2025)

Historic Accounts Payables for Roivant Sciences (ROIV) over the last 5 years, with Q4 2025 value amounting to $13.3 million.

  • Roivant Sciences' Accounts Payables fell 4393.56% to $13.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $13.3 million, marking a year-over-year decrease of 4393.56%. This contributed to the annual value of $23.7 million for FY2025, which is 6887.16% up from last year.
  • Per Roivant Sciences' latest filing, its Accounts Payables stood at $13.3 million for Q4 2025, which was down 4393.56% from $15.1 million recorded in Q3 2025.
  • Roivant Sciences' Accounts Payables' 5-year high stood at $161.3 million during Q2 2022, with a 5-year trough of $11.5 million in Q2 2025.
  • For the 5-year period, Roivant Sciences' Accounts Payables averaged around $37.2 million, with its median value being $26.4 million (2024).
  • Per our database at Business Quant, Roivant Sciences' Accounts Payables surged by 97435.73% in 2022 and then crashed by 6898.09% in 2023.
  • Roivant Sciences' Accounts Payables (Quarter) stood at $24.4 million in 2021, then surged by 97.06% to $48.0 million in 2022, then dropped by 26.61% to $35.2 million in 2023, then crashed by 32.69% to $23.7 million in 2024, then crashed by 43.94% to $13.3 million in 2025.
  • Its Accounts Payables stands at $13.3 million for Q4 2025, versus $15.1 million for Q3 2025 and $11.5 million for Q2 2025.